Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: a cumulative meta-analysis of randomized controlled trials
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1139 views | HTML 1692 views | ?
Zheng He1, Ting-Ting Zhao2, Hui-Mian Xu3, Zhen-Ning Wang3, Ying-Ying Xu2, Yong-Xi Song3, Zhong-Ran Ni3,4, Hao Xu5, Song-Cheng Yin3, Xing-Yu Liu3 and Zhi-Feng Miao3
1Department of Radiation Oncology, First Hospital of China Medical University, Shenyang, Liaoning Province, China
2Department of Breast Surgery, First Hospital of China Medical University, Shenyang, Liaoning Province, China
3Department of Surgical Oncology, First Hospital of China Medical University, Shenyang, Liaoning Province, China
4School of Life Science, University of Technology Sydney, Ultimo, New South Wales, Australia
5Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China
Zhi-Feng Miao, email: [email protected]
Keywords: gastric cancer, intraperitoneal chemotherapy, prognosis, meta-analysis
Received: July 10, 2017 Accepted: August 23, 2017 Published: September 11, 2017
Even when a curative gastrectomy is conducted, the majority of advanced gastric cancer patients with invasion die due to peritoneal recurrence. We performed electronic searches to identify randomized controlled trials published through April 2017 evaluating the effect of intraperitoneal chemotherapy (IPC) on survival rates. We included 23 trials reporting data on 2,767 patients with advanced gastric cancer. Overall, we noted that patients who received IPC had a significantly increased 1-year survival rate, and the treatment effect of IPC on 1-year survival was most prominent in studies conducted in Japan or those with a mean age of less than 60 years. IPC was also associated with an increased incidence of 2-year survival rate, but it was not seen to have this effect in studies conducted in China or Australia or with a mean age greater than 60 years. Similarly, IPC associated with a significantly increased 3-year survival rate, but this difference was not detected in studies conducted in Austria or with a mean age greater than 60 years. IPC has no significant effect on the 5-year survival rate. Finally, IPC was associated with a lower risk of recurrence in patients with advanced gastric cancer. The findings of this study suggest that gastric cancer patients who receive IPC associate with increased 1-year, 2-year, and 3-year survival rates, but this does not extend out to a 5-year survival rate. IPC is also shown to play a protective role against the risk of recurrence in patients with advanced gastric cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.